AR053595A1 - Forma purificada de tanaproget - Google Patents

Forma purificada de tanaproget

Info

Publication number
AR053595A1
AR053595A1 ARP060101667A ARP060101667A AR053595A1 AR 053595 A1 AR053595 A1 AR 053595A1 AR P060101667 A ARP060101667 A AR P060101667A AR P060101667 A ARP060101667 A AR P060101667A AR 053595 A1 AR053595 A1 AR 053595A1
Authority
AR
Argentina
Prior art keywords
degree
tanaproget
prepared
benzoxazin
thioxo
Prior art date
Application number
ARP060101667A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37000404&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR053595(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR053595A1 publication Critical patent/AR053595A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

También se proporcionan composiciones que contienen una o más de las formas de tanaproget preparadas, métodos de utilizacion de una o más de las formas de tanaproget preparadas, y kits que contienen una o mas de las formas tanaproget preparadas. Reivindicacion 1: Una forma micronizada de un compuesto, siendo el compuesto la Forma I de 5-(4,4-dimetil-2-tioxo-1,4- dihidro-2H-3,1-benzoxazin-6-il)-1-metil-1H-pirrol-2-carbonitrilo, cuya forma micronizada tiene un tamano de partícula medio inferior a aproximadamente 20 micrometros. Reivindicacion 6: Una Forma I purificada de 5-(4,4-dimetil-2-tioxo-1,4-dihidro-2H-3,1-benzoxazin-6-il)-1-metil-1H-pirrol-2-carbonitrilo que tiene: (i) un termograma de calorimetría por exploracion diferencial que tiene un punto endotérmico con una Tinicio a aproximadamente 230EC; y (ii) un patron de picos de difraccion de rayos X que comprende picos en 2theta de aproximadamente 6,6 degree , 10,3 degree , 14,4 degree , 19,8 degree , 23,8 degree , 26,3 degree y 29,1 degree .
ARP060101667A 2005-04-28 2006-04-26 Forma purificada de tanaproget AR053595A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67573805P 2005-04-28 2005-04-28

Publications (1)

Publication Number Publication Date
AR053595A1 true AR053595A1 (es) 2007-05-09

Family

ID=37000404

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101667A AR053595A1 (es) 2005-04-28 2006-04-26 Forma purificada de tanaproget

Country Status (14)

Country Link
US (1) US7786297B2 (es)
EP (1) EP1874743B1 (es)
JP (2) JP2008539254A (es)
CN (1) CN101184738B (es)
AR (1) AR053595A1 (es)
AU (1) AU2006241189B2 (es)
BR (1) BRPI0610156A2 (es)
CA (1) CA2603786A1 (es)
ES (1) ES2431324T3 (es)
GT (1) GT200600173A (es)
MX (1) MX2007013470A (es)
PE (1) PE20061322A1 (es)
TW (1) TW200716130A (es)
WO (1) WO2006116498A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE434434T1 (de) * 2005-04-28 2009-07-15 Wyeth Corp Zusammensetzungen mit mikronisiertem tanaproget
MX2007013469A (es) * 2005-04-28 2008-01-22 Wyeth Corp Forma ii polimorfa de tanaproget.
SI1896034T1 (sl) * 2005-04-28 2010-07-30 Wyeth Llc Mikronizirani sestavki tanaprogeta in postopki priprave le-tega
SI1877059T1 (sl) * 2005-04-28 2010-07-30 Wyeth Llc Mikroniziran tanaproget in sestavki, ki ga vsebujejo
CN103989687A (zh) 2005-06-09 2014-08-20 惠氏公司 含有炔雌醇的tanaproget组合物
AU2008341138A1 (en) * 2007-12-20 2009-07-02 Teva Women's Health, Inc. Dosage regimens and pharmaceutical compositions and packages for emergency contraception
WO2014143617A1 (en) * 2013-03-14 2014-09-18 Teva Women's Health, Inc. Deuterium-enriched tanaproget and processes for its preparation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100732692B1 (ko) * 1999-05-04 2007-06-27 와이어쓰 프로게스테론 수용체 조절인자인 시클로티오카르바메이트유도체
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
BR0312024A (pt) 2002-06-25 2005-03-22 Wyeth Corp Uso de derivados de ciclotiocarbamato no tratamento de condições relacionadas com hormÈnios
US7268149B2 (en) 2002-06-25 2007-09-11 Wyeth Cyclothiocarbamate derivatives as progesterone receptor modulators and methods of treating skin disorders
SV2005002092A (es) 2004-04-27 2005-12-13 Wyeth Corp " proceso de acoplamiento para la generacion de derivados reactivos de pirrol-2-carbonitrilo n-sustituidos con contenido de boro para producir biarilos " ref. am - 101481salvo.
AU2005237520B2 (en) * 2004-04-27 2012-01-19 Wyeth Purification of progesterone receptor modulators
BRPI0514273A (pt) 2004-08-13 2008-06-10 Wyeth Corp composto, kit para monitorar terapia com tanaproget, método para detectar metabólitos de tanaproget, anticorpo, composição, kit para detectar metabólicos de tanaproget, e, uso de um derivado de glucuronìdeo de tanaproget ou um seu sal farmaceuticamente aceitável

Also Published As

Publication number Publication date
PE20061322A1 (es) 2006-12-28
CN101184738B (zh) 2012-05-23
ES2431324T3 (es) 2013-11-26
US20060247236A1 (en) 2006-11-02
JP2013231042A (ja) 2013-11-14
US7786297B2 (en) 2010-08-31
CA2603786A1 (en) 2006-11-02
EP1874743A2 (en) 2008-01-09
JP2008539254A (ja) 2008-11-13
AU2006241189B2 (en) 2012-01-19
EP1874743B1 (en) 2013-07-17
CN101184738A (zh) 2008-05-21
BRPI0610156A2 (pt) 2016-08-16
WO2006116498A3 (en) 2006-12-14
TW200716130A (en) 2007-05-01
AU2006241189A1 (en) 2006-11-02
MX2007013470A (es) 2008-01-22
GT200600173A (es) 2006-11-22
WO2006116498A2 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
AR053595A1 (es) Forma purificada de tanaproget
LTC1856135I2 (lt) 2,4-pirimidindiamino junginių provaistai ir jų panaudojimas
ECSP045255A (es) Cumarinas utiles como biomarcadores
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
AR057237A1 (es) Metodos y composiciones para actuar sobre la poliubiquitina
RS52183B (en) CRYSTAL SOLID RAZAGILINE BASE
UY27668A1 (es) Composición de ziprasidona y controles sintéticos
RS50629B (sr) Amidni prolek gemcitabina, kompozicije i njihova primena
DE60329702D1 (de) Polymerische parfümpartikel
CY1112950T1 (el) Νηματωδοκτονες συνθεσεις
EA200870097A1 (ru) Композиция полипропилена, включающая компонент сополимера пропилена
DK1664162T3 (da) Polypropylen-blæsefolie
DE602005009977D1 (de) Tetralin- und indanderivate und deren anwendungen als 5-ht-antagonisten
ATE478125T1 (de) Reversible thermochromische zusammensetzungen
ATE374190T1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
EA200601596A1 (ru) Улучшенный состав 6-меркаптопурина
ATE254455T1 (de) Wassermischbare pharmazeutische zusammensetzungen enthaltend paclitaxel
ATE514765T1 (de) Azeotropartige zusammensetzungen mit 1,1,1,2,3,3- hexafluor-3-methoxypropan und 1-brompropan
DE60310936D1 (de) Riechstoffzusammensetzung
BR9713176A (pt) Benzotiofenos amorfos,métodos de preparação e métodos de uso
DE602005021978D1 (de) Quecksilberfreie zusammensetzungen und strahlungsquellen damit
BRPI0412721A (pt) processo para preparar bromidrato de eletriptano alfa-polimórfico
AR061300A1 (es) Formas cristalinas de 6-metoxi -8- [4- (1- (5-fluoro) -quinolin -8-il-piperidin -4-il) -piperazin -1-il] -quinolina
DE50107490D1 (de) Stoffgemisch enthaltend bisphenol a
ATE489368T1 (de) Pyrimidinonverbindungen als calcilytica

Legal Events

Date Code Title Description
FA Abandonment or withdrawal